Efficacy and Safety of IBI308 and Paclitaxel/Albumin Paclitaxel for SCLC Patients Who Failed Etoposide Chemotherapy

Extensive-Stage Small Cell Lung Cancer Clinical Trial

Official title:

The Efficacy and Safety of IBI308 Combined With Paclitaxel/Albumin-Bound Paclitaxel as Second-Line Therapy in Treating Patients With Extensive-Stage Small Cell Lung Cancer That Relapsed After Failing to Platinum-Etoposide Chemotherapy

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04056949
• Other study ID #: NCC1977
• Status: Recruiting
• Phase: Phase 2
• Start date: August 5, 2019
• Est. completion date: December 31, 2021

Study information

• Verified date: August 2019
• Source: Peking Union Medical College
• Contact: Junling Li, doctor
• Phone: +86 13801178891
• Email: lijunling[@]cicams.ac.cn
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This phase II trial studies how well IBI308 combined with paclitaxel/albumin-bound paclitaxel work in treating participants with small cell lung cancer after failing to platinum-etoposide chemotherapy.

Description:

Primary objective :

To estimate progression free survival (PFS) probability of patient who recurrent SCLC treated with IBI308 combined with paclitaxel/abumin-bound paclitaxel following progression on platinum-etoposide chemotherapy.

Secondary Objectives:

I.To evaluate the objective remission rate (ORR), disease control rate. (DCR),durative time of remission ( DoR）and overall survival (OS) of IBI308 combined with paclitaxel/abumin-bound paclitaxel following progression on platinum-etoposide chemotherapy.

II.To evaluate the safety of IBI308 combined with paclitaxel/abumin-bound paclitaxel following progression on platinum-etoposide chemotherapy.

Exploratory Objectives To evaluate the correlation of biomarkers with efficacy and toxicity.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 30
• Est. completion date: December 31, 2021
• Est. primary completion date: February 1, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 70 Years

Eligibility

Inclusion Criteria:

1. Signed informed consent;

2. Over 18 years old and below 70 years old;

3. Histologically confirmed small-cell lung cancer;

4. Extensive disease(ED) according to the criteria of the Veteran's Administration Lung Cancer Group: (disease extended is defined as a disease beyond hemi thorax and supraclavicular lymph node areas.);

5. ED-SCLC treated with platinum-etoposide chemotherapy ,followed by disease progression or recurrence.

6. Availability of a biomarker detection tissue biopsy is required;

7. Eastern Cooperative Oncology Group (ECOG) performance status 0~1;

8. Life expectancy of greater than 12 weeks;

9. Participants may have evaluable or measurable disease, defined as at least one lesion(no previous radiotherapy)that can be accurately measured in at least one dimension with spiral CT scan, MRI within the past 28 days;

10. Women of child-bearing potential and men must agree to use adequate contraception prior to initiation of therapy and until to 6 month after this study;

11. White blood cell = 3.5 × 109/L, absolute neutrophil count =1.5 × 109/L, platelet =100× 109/L and hemoglobin =9.0 g/dL;

12. Aspartate transferase,alanine aminotransferase = 2.5 x ULN except in case of liver metastases (5 x ULN); Total bilirubin =1.5 x ULN except in case of Gilbert syndrome (3.0 mg/dL); Albumin=3 g/dL;

13. Serum creatinine =1.5×ULN OR creatinine clearance=40 mL/min;

14. Lipase < 1.5 x ULN except in case of having no clinical or imaging evidence of pancreatitis; Amylase =1.5 x ULN except in case of having no clinical or imaging evidence of pancreatitis; Alkaline phosphatase (ALP) = 2.5 ULN except in case of bone metastasis;

Exclusion Criteria:

1. Mixed lung cancer or other types of lung cancer;

2. Prior immunotherapy, included but not limited to cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) inhibitors, PD-1 inhibitors, PD-L1/2 inhibitors or other drugs targeting T cells;

3. Received high-dose radiation therapy in thoracic field within the past 6 months, Dt (> 30 Gy);

4. Active or untreated central nervous system (CNS) metastases;

5. Patients with cytologically positive pleural, peritoneal or pericardial fluid are not eligible;

6. History of autoimmune disease.Patients with a history of hypothyroidism origin autoimmune treated with a stable dose replacement therapy may be eligible for this study. Patients with controlled type 1 diabetes treated with insulin are eligible in this study;

7. Corticosteroid with a daily dose over 10 mg prednisolone or other immunosuppressive agents were used within 14 days before the first cycle;

8. Patients should not receive a vaccine during the four weeks preceding the day 1 of cycle 1, and shall not receive a vaccine during the study;

9. Idiopathic pulmonary fibrosis history, radioactive pneumonia requiring steroid therapy, organizing pneumonia (eg, bronchiolitis obliterans), drug-induced lung disease, idiopathic pulmonary or active signs of pneumonia or interstitial lung infiltrate (any cause) detected on the lung scan selection;

10. History of active Bacillus Tuberculosis;

11. Except hair loss and fatigue, toxicities caused by previous anti-cancer therapies need to be restored to < CTCAE 4.03 grade 1 before starting treatment on protocol;

12. History of any one or more of the following conditions within the past 6 months:symptomatic peripheral vascular disease, pulmonary embolism or untreated deep venous thrombosis (DVT), cerebrovascular accident or transient ischemic attack;

13. History of any one or more of the following conditions within the past 6 months:

gastrointestinal ulcer, gastrointestinal perforation, corrosive esophagitis or gastritis, inflammatory bowel disease or diverticulitis, abdominal fistula, tracheoesophageal fistula or abdominal abscess;

14. History of any one or more of the following cardiovascular conditions: Class III or IV congestive heart failure, as defined by the New York Heart Association; Unstable angina; Myocardial infarction within the past 6 months; Supraventricular or ventricular arrhythmia requires treatment or intervention;

15. Severe uncontrolled hypertension (systolic blood pressure =160 mmHg and/or diastolic blood pressure = 100mmHg);

16. Tumors compress surrounding vital organs, such as the esophagus, with associated symptoms;

17. Uncontrolled hypercalcemia;

18. History of allergic reactions attributed to compounds of similar chemical or biologic composition to monoclonal antibody;

19. Prior malignancy. Note: Patients who have had another malignancy and were treated more than 5 years ago and have since been considered cured, or patients with a history of basocellular skin carcinoma or in situ carcinoma of the uterine cervix are eligible;

20. Mental illness, alcoholism, inability to quit smoking, drug abuse or drug abuse;

21. History of human immunodeficiency virus infection or has known active Hepatitis B (e.g., HBsAg reactive) or Hepatitis C Virus (HCV) (e.g., HCV RNA is detected).

22. Pregnant or lactating female;

23. Any type of systemic anticancer therapy (chemotherapy or experimental drugs) within 4 weeks of starting treatment on protocol;

24. Other situations judged by researchers;

Related Conditions & MeSH terms

• Extensive-Stage Small Cell Lung Cancer
• Lung Neoplasms
• Small Cell Lung Carcinoma

Intervention

Drug:
• Paclitaxel/Albumin-Bound Paclitaxel
Paclitaxel 175mg/m2 IV on day 1of 21 days cycle ;Number of Cycles: 4-6; or Albumin-bound paclitaxel 130mg/m2 IV on day 1 and 8 of 21 days cycle ;Number of Cycles: 4-6;
• IBI308
IBI308 200mg IV infusion, every 3 weeks,until disease progress or intolerable toxicity,used up to 1 year (or 16 cycles)

Locations

Country	Name	City	State
China	Junling Li	Beijing	Beijing

Sponsors (1)

Lead Sponsor	Collaborator
Junling Li

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	progression-free survival (PFS)		12 months
Secondary	overall survival (OS)		12 months
Secondary	disease control rate (DCR)		12 months
Secondary	durative time of remission ( DoR)		12 months
Secondary	objective remission rate (ORR)		12 months